Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Cardiol. Jun 26, 2025; 17(6): 106717
Published online Jun 26, 2025. doi: 10.4330/wjc.v17.i6.106717
Table 2 Vital signs and electrocardiographic measures of the included patients
Variable
Transient improvement (n = 39)
Sustained improvement (n = 136)
P value
Baseline (Echo-1), mean ± SD
Systolic BP (mmHg)124.38 ± 22.41125.30 ± 20.1 (n = 134)0.81
Diastolic BP (mmHg)72.64 ± 12.3675.97 ± 12.99 (n = 134)0.16
Heart rate (bpm)86.43 ± 18.02 (n = 37)89.69 ± 19.12 (n = 132)0.36
Achieved target BP26 (66.7)87 (64.9)1.00
Sinus rhythm28 (90.3)103 (86.6)0.77
LBBB7 (14.1)19 (17.1)0.42
QRS (ms), mean ± SD109.45 ± 26.29 (n = 29)109.43 ± 44.04 (n = 129)1.0
QTc (ms), mean ± SD468.86 ± 43.48 (n = 29)462.84 ± 52.19 (n = 109)0.57
Second follow-up (Echo-3), mean ± SD
Systolic BP (mmHg)127.87 ± 21.43133.47 ± 98.18 (n = 129)0.73
Diastolic BP (mmHg)73.85 ± 13.6273.81 ± 11.49 (n = 129)0.99
Heart rate (bpm)79.41 ± 15.4572.84 ± 12.90 (n = 128)0.02
Achieved target BP26 (66.7)90 (69.8)0.67
Sinus rhythm33 (89.2)111 (88.8)1.00
LBBB7 (19.4)21 (17.4)0.81
QRS (ms), mean ± SD112.00 ± 26.87 (n = 37)110.07 ± 26.34 (n = 120)0.70
QTc (ms), mean ± SD455.08 ± 31.57 (n = 37)448.91 ± 42.92 (n = 120)0.35